DDInter385 DDInter1376
In many countries (including Canada) cisapride has been either withdrawn or has had its indications limited due to reports about long QT syndrome due to cisapride, which predisposes to arrhythmias. The FDA issued a warning letter regarding this risk to health care professionals and patients.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Cisapride {u} (Compound) resembles {v} (Compound) Metoclopramide
Cisapride {u} may lead to a major life threatening interaction when taken with {v} Iloperidone
Cisapride {u} (Compound) binds {v} (Gene) HTR2B
Cisapride {u} (Compound) upregulates {v} (Gene) PAK1
Cisapride {u} (Compound) downregulates {v} (Gene) PUF60
Cisapride {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sulfamethoxazole
Cisapride {u} may cause a minor interaction that can limit clinical effects when taken with {v} Morphine
Cisapride {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nevirapine
Cisapride {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Erdafitinib
Cisapride {u} may lead to a major life threatening interaction when taken with {v} Haloperidol
Cisapride (Compound) resembles Metoclopramide (Compound)
Cisapride may lead to a major life threatening interaction when taken with Iloperidone
Cisapride (Compound) binds HTR2B (Gene)
Cisapride (Compound) upregulates PAK1 (Gene)
Cisapride (Compound) downregulates PUF60 (Gene)
Cisapride may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole
Cisapride may cause a minor interaction that can limit clinical effects when taken with Morphine
Cisapride may cause a moderate interaction that could exacerbate diseases when taken with Nevirapine
Cisapride may cause a moderate interaction that could exacerbate diseases when taken with Erdafitinib
Cisapride may lead to a major life threatening interaction when taken with Haloperidol